As the only cells definitively shown to degrade bone, osteoclasts are key mediators of
skeletal diseases including osteoporosis. Bone-forming osteoblasts, and hematopoietic and …

Giant Cell tumors (GCT) are benign tumors with potential for aggressive behavior and
capacity to metastasize. Although rarely lethal, benign bone tumors may be associated with …

Background Giant-cell tumour (GCT) of bone is a primary osteolytic bone tumour with low
metastatic potential and is associated with substantial skeletal morbidity. GCT is rich in …

Purpose: Giant-cell tumor of bone (GCTB) is a locally aggressive, benign osteolytic tumor in
which bone destruction is mediated by RANK ligand (RANKL). The RANKL inhibitor …

Background Many surgeons treat giant cell tumor of bone (GCT) with intralesional curettage.
Wide resection is reserved for extensive bone destruction where joint preservation is …

We provide an overview of imaging, histopathology, genetics, and multidisciplinary
treatment of giant cell tumor of bone (GCTB), an intermediate, locally aggressive but rarely …

Osteonecrosis of the jaw (ONJ) presents clinically as exposed, necrotic bone in the maxilla
or mandible of at least 8 weeks' duration, with or without the presence of pain, infection, or …

Giant cell tumor (GCT) of bone is a locally aggressive benign neoplasm that is associated
with a large biological spectrum ranging from latent benign to highly recurrent and …

Giant cell tumor (GCT) of bone is one type of giant cell‐rich lesion of bone. This benign
mesenchymal tumor has characteristic multinuclear giant cells. Mononuclear stromal cells …

Giant cell tumour of bone (GCTB) is an intermediate locally aggressive primary bone tumour,
occurring mostly at the meta-epiphysis of long bones. Overexpression of receptor activator of …